Yeo, Winnie
,
Ueno, Takayuki
Lin, Ching-Hung
Liu, Qiang http://orcid.org/0000-0002-5451-4862
Lee, Kyung-Hun
Leung, Roland
Naito, Yoichi
Park, Yeon Hee
Im, Seock-Ah
Li, Huiping
Yap, Yoon Sim
Lu, Yen-Shen http://orcid.org/0000-0001-7461-1291
Article History
Received: 4 June 2019
Accepted: 8 June 2019
First Online: 4 July 2019
Compliance with ethical standards
:
: The authors have all participated as faculty members of Novartis Breast Cancer Advisory Boards, and received personal fees, reimbursement of travel expenses, and/or hospitality for their service in this capacity. However, the ABCCG is a professional association that was constituted and operates independently of Novartis and which sets its own research agenda. The article discusses specific Novartis products within the context of the current breast cancer therapeutic landscape, which the authors strove to review impartially. All views expressed are the authors’ own, and do not necessarily represent those of Novartis. The authors declare competing interests. WY reports consultancy/advisory roles and receipt of personal fees for Novartis, Pfizer, AstraZeneca, Eli Lilly, Roche, and Amgen. TU reports receiving personal fees and non-financial support from Novartis KK, and personal fees from Chugai, Eisai, AstraZeneca KK, and Taiho. CHL reports a consultancy/advisory role for Novartis. QL reports a consultancy/advisory role and personal fees for Novartis, and receipt of personal fees from Pfizer, Roche, AstraZeneca, and Eisai. KHL reports consultancy/advisory roles with Novartis, AstraZeneca, Roche, Ono, Eisai, Bayer, and Samsung Bioepis. RL reports a consultancy/advisory role with Novartis. YN reports research funding and a consultancy/advisory role for Roche Diagnostics, and consultancy/advisory roles for Novartis, Pfizer, Taiho, Nippon Kayaku, Eli Lilly, AstraZeneca, Merck Serono, Bayer, Meiji Seika, Chugai, and Eisai. YHP reports research funding and consultancy/advisory roles for Novartis, Pfizer, Eisai, and research funds from AstraZeneca, and Roche. SAI reports research funding from AstraZeneca, research funds and a consultancy/advisory role for Pfizer, and consultancy/advisory roles with Novartis, Hanmi, Roche, Pfizer, Amgen, and Eisai. HL reports research funding and a consultancy/advisory role for Roche Diagnostics, and consultancy/advisory roles with Novartis, Pfizer, Eli Lilly, and AstraZeneca. YSY reports personal fees and a consultancy/advisory role for Novartis, receiving personal fees and non-financial support from Pfizer, AstraZeneca, Lilly, and non-financial support from Eisai, and Roche. YSL reports receiving research funds and personal fees from Novartis, Pfizer, Roche, and Merck Sharp & Dohme, and personal fees from Boehringer Ingelheim.
: This work did not entail studies of human participants by any of the authors.